Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Recalls, complaints & regulation

Kiniksa Pharmaceuticals International (KNSA): clinical trials

Kiniksa Pharmaceuticals International (KNSA) beyond its filings: 3 active clinical trials.

Kiniksa Pharmaceuticals International's latest quarter

Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Kiniksa Pharmaceuticals International have?

3 active studies on ClinicalTrials.gov, 1 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.